CVS Health Corporation (CVS)
Buy CVS Stock Ahead of Its Upcoming Earnings?
CVS Health (NYSE:CVS) is scheduled to announce its earnings on Thursday, July 31, 2025. For event-driven traders, analyzing the stock's historical behavior around earnings releases can provide valuable context.
Thousands of Americans are being forced to switch from Zepbound to Wegovy as a result of new coverage restrictions by CVS Caremark. ‘I just wish they would trust my doctor.
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.
Here's Why CVS Health (CVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health (CVS) Stock Slides as Market Rises: Facts to Know Before You Trade
In the most recent trading session, CVS Health (CVS) closed at $58.75, indicating a -5.01% shift from the previous trading day.
CVS Health (CVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?
Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
What's Shaping CVS' Health Care Benefits Arm for the Rest of 2025?
CVS Health's Health Care Benefits arm posts solid Medicare gains and prepares for an ACA exit with a $448M reserve.
Here's Why CVS Health (CVS) is Poised for a Turnaround After Losing 7.7% in 4 Weeks
CVS Health (CVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CVS Health Has Become A Strong GARP Pick (Rating Upgrade)
This article upgrades my rating on CVS Health to 'Buy' as recent negative industry headlines have pressured its valuation. These negatives are fully priced in already, creating a strong GARP (growth at a reasonable price) opportunity. Despite margin pressures, robust EPS growth is projected at double-digit rates. Yet, the forward P/E is just 10x.
Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
